Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Tollefson, C. Beasley, P. Tran, J. Street, J. Krueger, R. Tamura, Karin Graffeo, Martha Thieme (1997)
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.The American journal of psychiatry, 154 4
Richard Owen, B. Beake, D. Marby, Dessain Ec, Jonathan Cole (1989)
Response to clozapine in chronic psychotic patients.Psychopharmacology bulletin, 25 2
Alice Medalia, James Gold, Arnold Merriam (1988)
The effects of neuroleptics on neuropsychological test results of schizophrenics.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists, 3 3
Cardwell Ba, B. Nakai (1995)
Seizure activity in combined clozapine and ECT: a retrospective view.Convulsive therapy, 11 2
G Bersani, GM Bressa, G Meco (1990)
Combined 5HT2 and dopamine D2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidoneHuman Psychopharmacology, 5
T. Goldberg, Daniel Weinberger (1994)
The effects of clozapine on neurocognition: an overview.The Journal of clinical psychiatry, 55 Suppl B
JM Alvir, JA. Lieberman (1994)
Agranulocytosis: Incidence and risk factorsJournal of Clinical Psychiatry, 55/9
A. Wood, J. Kane (1996)
Drug therapy : schizophreniaThe New England Journal of Medicine, 334
JM Kane, G Honigfeld, J Singer, H Meltzer (1988)
Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropineArch Gen Psych, 45
P. Janicak (1993)
Principles and Practice of Psychopharmacotherapy
J. Lieberman, J. Kane, A. Safferman, S. Pollack, A. Howard, S. Szymanski, S. Masiar, M. Kronig, T. Cooper, H. Novacenko (1994)
Predictors of response to clozapine.The Journal of clinical psychiatry, 55 Suppl B
M. Green, B. Marshall, W. Wirshing, D. Ames, S. Marder, S. McGurk, R. Kern, J. Mintz (1997)
Does risperidone improve verbal working memory in treatment-resistant schizophrenia?The American journal of psychiatry, 154 6
J. Lieberman, D. Jody, S. Geisler, J. Alvir, A. Loebel, S. Szymanski, M. Woerner, M. Borenstein (1993)
Time course and biologic correlates of treatment response in first-episode schizophrenia.Archives of general psychiatry, 50 5
R. Cavallaro, C. Colombo, E. Smeraldi (1995)
A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapineHuman Psychopharmacology: Clinical and Experimental, 10
J. Kane, G. Honigfeld, J. Singer, H. Meltzer (1988)
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.Archives of general psychiatry, 45 9
C. Beasley, G. Tollefson, P. Tran, W. Satterlee, T. Sanger, S. Hamilton (1996)
Olanzapine versus Placebo and HaloperidolNeuropsychopharmacology, 14
A. Koreen, J. Lieberman, M. Kronig, T. Cooper (1995)
Cross-tapering clozapine and risperidone.The American journal of psychiatry, 152 11
P. Czobor, J. Volavka, R. Meibach (1995)
Effect of risperidone on hostility in schizophrenia.Journal of clinical psychopharmacology, 15 4
B. Kinon, John Kane, Celeste Johns, R. Perovich, M. Ismi, A. Koreen, Peter Weiden (1993)
Treatment of neuroleptic-resistant schizophrenic relapse.Psychopharmacology bulletin, 29 2
JM. Kane (1996)
SchizophreniaN Engl J Med, 334
G. Chouinard, B. Jones, G. Remington, D. Bloom, D. Addington, G. Macewan, A. Labelle, L. Beauclair, W. Arnott (1993)
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.Journal of clinical psychopharmacology, 13 1
D. Landy (1991)
Combined Use of Clozapine and Electroconvulsive Therapy.Convulsive therapy, 7 3
R. Kavoussi, Jennifer Liu, E. Coccaro (1994)
An open trial of sertraline in personality disordered patients with impulsive aggression.The Journal of clinical psychiatry, 55 4
H. Sackeim, J. Prudic, D. Devanand, J. Kiersky, L. Fitzsimons, Bobba Moody, M. McElhiney, E. Coleman, J. Settembrino (1993)
Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy.The New England journal of medicine, 328 12
J. McEvoy, G. Hogarty, S. Steingard (1991)
Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.Archives of general psychiatry, 48 8
G. Bersani, G. Bressa, G. Meco, S. Marini, F. Pozzi (1990)
Combined serotonin‐5‐HT2 and dopamine‐D2 antagonism in schizophrenia: Clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766)Human Psychopharmacology: Clinical and Experimental, 5
A. Safferman, R. Munne (1992)
Combining Clozapine with ECT.Convulsive therapy, 8 2
G. Bondolfi, P. Baumann, M. Patris, J. May, U. Billeter, H. Dufour (1995)
P-4-73 A randomized double-bind trial of risperidone versus clozapine for treatment-resistant chronic schizophreniaEuropean Neuropsychopharmacology, 5
CM Beasley, G Tollefson, P Tran (1996)
Olanzapine versus placebo and haloperidol:Acute phase results of the NorthAmerican double-blind trialNeuropsychopharmacology, 14
McCarthy Rh, Terkelsen Kg (1995)
Risperidone Augmentation of ClozapinePharmacopsychiatry, 28
G. Tollefson, Sanger Tm (1997)
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.The American journal of psychiatry, 154 4
HY Meltzer, B Bastani, K Youngkwon (1989)
A prospective study of clozapine in treatment-resistant schizophrenic patients, I: preliminary reportPsychopharmacology (Berl), 99
S. Kimmel, J. Calabrese, M. Woyshville, Herbert Meltzer (1994)
Clozapine in treatment-refractory mood disorders.The Journal of clinical psychiatry, 55 Suppl B
S. Marder, R. Meibach (1994)
Risperidone in the treatment of schizophrenia.The American journal of psychiatry, 151 6
P. Weiden, A. Manevitz, L. Dixon, J. Sweeney, G. Haas, A. Frances (1989)
Neuroleptic noncompliance in schizophreniaSchizophrenia Research, 2
S. Hoge, Paul Appelbaum, Ted Lawlor, James Beck, Robert Litman, Alexander Greer, T. Gutheil, Eric Kaplan (1990)
A prospective, multicenter study of patients' refusal of antipsychotic medication.Archives of general psychiatry, 47 10
J. Kane (1994)
The Use of Higher-Dose Antipsychotic MedicationBritish Journal of Psychiatry, 164
PJ Weiden, L Dixon, A Frances (1991)
Advances in Neuropsychiatry and Psychopharmacology, Vol 1: Schizophrenia Research
Herbert Meltzer, B. Bastani, K. Kwon, Luis Ramirez, S. Burnett, J. Sharpe (2004)
A prospective study of clozapine in treatment-resistant schizophrenic patientsPsychopharmacology, 99
S. Siris (1991)
Diagnosis of secondary depression in schizophrenia: implications for DSM-IV.Schizophrenia bulletin, 17 1
D. Casey (1994)
Motor and mental aspects of acute extrapyramidal syndromesActa Psychiatrica Scandinavica, 89
L. Opler, M. Hwang (1994)
Schizophrenia: A Multidimensional DisorderPsychiatric Annals, 24
GD Tollefson, CM Beasley, P Tran (1997)
Olanzapine versus haloperidol in thetreatment of schizophreniaand schizophreniform disorders. Results of an international collaborative trialAm J Psychiatry, 154
S. Potkin, R. Bera, B. Gulasekaram, Jerome Costa, S. Hayes, Y. Jin, G. Richmond, D. Carreon, K. Sitanggan, B. Gerber (1994)
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.The Journal of clinical psychiatry, 55 Suppl B
John Kane, M. Woerner, Jeffrey Lieberman (1988)
Tardive dyskinesia: prevalence, incidence, and risk factors.Journal of clinical psychopharmacology, 8 4 Suppl
A substantial portion of schizophrenic patients demonstrate suboptimal response to conventional antipsychotics. These agents are primarily effective in the treatment of psychotic symptoms; their efficacy in other domains of psychopathology such as negative symptoms, chronic aggressive behavior, and cognitive deficits, is limited or non-existent. In this group of refractory patients, the novel atypical antipsychotic clozapine has demonstrated robust efficacy, with response rates approaching 60% after twelve weeks of treatment. Efficacy of clozapine extends to symptom domains other than psychosis, including negative symptoms, mood stabilization, aggressive behavior and compulsive water drinking. Several novel agents, each of which shares some, but not all, of the preclinical and clinical characteristics that make clozapine so unique, have been introduced in the last 4 years. These agents demonstrate a broader spectrum of efficacy and an improved side effect profile in non-refractory patients. Initial data on their efficacy in refractory patients suggests that olanzapine does not achieve overall superior efficacy in this patient population compared to conventional agents although there is some evidence of relatively greater efficacy in negative symptoms and aggressivity. Several studies suggest that the efficacy of risperidone is superior to that of conventional agents in refractory patients. Preliminary conclusions are not possible for quetiapine because of a paucity of data in the literature. The literature supports a risperidone trial prior to a clozapine trial in a treatment algorithm for refractory patients because of its more favorable risk/benefit profile.
Psychiatric Quarterly – Springer Journals
Published: Oct 6, 2004
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.